Kidney health for everyone everywhere. From prevention to detection and equitable access to care
References
2) Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052-90.
3) Essue BM, Laba T, Knaul F, Chu A, Van Minh H, Phuong Nguyen TH, et al. Economic burden of chronic ill health and injuries for households in low- and middle-income countries. In: Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mock CN, et al., eds. Disease control priorities: improving health and reducing poverty 3rd ed. Washington, DC: World Bank, 2018, p. 121-43.
4) Luyckx VA, Tuttle KR, Garcia-Garcia G, Gharbi MB, Heerspink HJL, Johnson DW, et al. Reducing major risk factors for chronic kidney disease. Kidney Int Suppl. 2017;7(2):71-87.
5) Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018; 96(6):414-22D.
6) Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844): 807-14.
7) Kalantar-Zadeh K, Fouque D. Nutritional management of chronic kidney disease. N Engl J Med. 2017;377(18):1765-76.
8) United Nations General Assembly. Political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases [Internet]. Oct. 2018. Disponible en: https://www.un.org/ga/search/view_doc.asp?symbol=A/73/L.2&Lang=E (Consulta: 20/07/2019).
9) López AD, Williams TN, Levin A, Tonelli M, Singh JA, Burney PG, et al. Remembering the forgotten non-communicable diseases. BMC Med. 2014;12:200.
10) Estados Unidos. Centers for Disease Control and Prevention. Picture of America [Internet]. Washington DC: CDC, 2019. Disponible en: https://www.cdc.gov/pictureofamerica/index.html (Consulta: 20/07/2019).
11) Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClellan W. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis. 2009;53(3):522-35.
12) Saran R, Robinson B, Abbott KC, Agodoa LYC, Bragg-Gresham J, Balkrishnan R, et al. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2019;73(3S1):A7-A8.
13) Kovesdy CP, Furth SL, Zoccali C; World Kidney Day Steering Committee. Obesity and kidney disease: hidden consequences of the epidemic. J Ren Nutr. 2017;27(2):75-7.
14) Tantisattamo E, Dafoe DC, Reddy UG, Ichii H, Rhee CM, Streja E, et al. Current management of acquired solitary kidney. Kidney Int Rep. 2019;4(9):1205-18.
15) Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238-52.
16) Koppe L, Fouque D. The role for protein restriction in addition to renin-angiotensin-aldosterone system inhibitors in the management of CKD. Am J Kidney Dis. 2019;73(2):248-57.
17) Rifkin DE, Coca SG, Kalantar-Zadeh K. Does AKI truly lead to CKD? J Am Soc Nephrol. 2012;23(6):979-84.
18) Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407-18.
19) Verhave JC, Troyanov S, Mongeau F, Fradette L, Bouchard J, Awadalla P, et al. Prevalence, awareness, and management of CKD and cardiovascular risk factors in publicly funded health care. Clin J Am Soc Nephrol. 2014;9(4):713-9.
20) Chow KM, Szeto CC, Kwan B, Leung CB, Li PK. Public lacks knowledge on chronic kidney disease: telephone survey. Hong Kong Med J. 2014;20(2):139-44.
21) Ene-Iordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health. 2016;4(5):e307-19.
22) Li PK, Weening JJ, Dirks J, Lui SL, Szeto CC, Tang S, et al. A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney Int Suppl. 2005;(94):S2-7.
23) Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis. 2007;50(2):169-80.
24) Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72(3):247-59.
25) Crowe E, Halpin D, Stevens P; Guideline Development Group. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ. 2008;337:a1530.
26) Li PK, Chow KM, Matsuo S, Yang CW, Jha V, Becker G, et al. Asian chronic kidney disease best practice recommendations: positional statements for early detection of chronic kidney disease from Asian Forum for Chronic Kidney Disease Initiatives (AFCKDI). Nephrology (Carlton). 2011;16(7):633-41.
27) Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012;156(8):570-81.
28) Li PK, Ng JK, Cheng YL, Kwan TH, Leung CB, Lau MF, et al. Relatives in silent kidney disease screening (RISKS) study: A Chinese cohort study. Nephrology (Carlton). 2017;22(Suppl. 4):35-42.
29) Samal L, Linder JA. The primary care perspective on routine urine dipstick screening to identify patients with albuminuria. Clin J Am Soc Nephrol. 2013;8(1):131-5.
30) George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP. Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ Glob Health. 2017;2(2):e000256.
31) Gonzalez-Quiroz M, Nitsch D, Hamilton S, O'Callaghan Gordo C, Saran R, Glaser J, et al. Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE). BMJ Open. 2019;9(9):e031169.
32) Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290(23):3101-14.
33) Go DS, Kim SH, Park J, Ryu DR, Lee HJ, Jo MW. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea. Nephrology (Carlton). 2019;24(1):56-64.
34) Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014;63(5):789-97.
35) Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton). 2010;15(Suppl. 2):3-9.
36) Almaguer M, Herrera R, Alfonso J, Magrans C, Mañalich R, Martínez A. Primary health care strategies for the prevention of end-stage renal disease in Cuba. Kidney Int. 2005;68( 97):S4-10.
37) Alamaguer-López M, Herrera-Valdez R, Díaz J, Rodríguez O. Integration of chronic kidney disease prevention into noncommunicable disease programs in Cuba. En: G. García-García, LY Agodoa, KC Norris (eds.). Chronic kidney disease in disadvantaged population. London: Elsevier, 2017, pp. 357-65.
38) Estados Unidos. Department of Health and Human Services. Advancing american kidney health [Internet]. Disponible en: https://aspe.hhs.gov/system/files/pdf/262046/AdvancingAmericanKidneyHealth.pdf (Consulta: 20/07/2019).
39) Estados Unidos. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. The Special Diabetes Program for Indians. Estimates of Medicare savings [Internet]. ASPE Issue Brief, may 10 2019. Disponible en: https://aspe.hhs.gov/system/files/pdf/261741/SDPI_Paper_Final.pdf (Consulta: 26/09/2019).
40) Bello AK, Nwankwo E, El Nahas AM. Prevention of chronic kidney disease: a global challenge. Kidney Int Suppl. 2005;(98):S11-7.
41) James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet. 2010; 375(9722):1296-309.
42) Cortés-Sanabria L, Cabrera-Pivaral CE, Cueto-Manzano AM, Rojas-Campos E, Barragán G, Hernández-Anaya M, et al. Improving care of patients with diabetes and CKD: a pilot study for a cluster-randomized trial. Am J Kidney Dis. 2008;51(5):777-88.
43) Martínez-Ramírez HR, Jalomo-Martínez B, Cortés-Sanabria L, Rojas-Campos E, Barragán G, Alfaro G, et al. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist. Am J Kidney Dis. 2006;47(1):78-87.
44) Cueto-Manzano AM, Martínez-Ramírez HR, Cortes-Sanabria L, Rojas-Campos E. CKD screening and prevention strategies in disadvantaged populations. The role of primary health care professionals. En: G. Garcia-Garcia, LY Agodoa, KC Norris (eds.). Chronic kidney disease in disadvantaged population. London: Elsevier, 2017, pp. 329-35.
45) Tapia-Conyer R, Gallardo-Rincon H, Betancourt-Cravioto M. Chronic kidney disease in disadvantaged populations: Online educational programs for NCD prevention and treatment. En: G. Garcia-Garcia, LY Agodoa, KC Norris (eds.). Chronic kidney disease in disadvantaged population. London: Elsevier, 2017, pp. 337-45.
46) Bello AK, Levin A, Manns BJ, Feehally J, Drueke T, Faruque L, et al. Kidney Health for Life Initiative. Effective CKD care in european countries: challenges and opportunities for health policy. Am J Kidney Dis. 2015;65(1):15-25.
47) Sharif MU, Elsayed M E, Stack AG. The global nephrology workforce: emerging threats and potential solutions. Clin Kidney J. 2016;9(1):11-22.
48) Naicker S, Eastwood JB, Plange-Rhule J, Tutt RC. Shortage of healthcare workers in sub-Saharan Africa: a nephrological perspective. Clin Nephrol. 2010;74(Suppl 1):S129-33.
49) Cusumano AM, Rosa-Diez GJ, González-Bedat MC. Latin American Dialysis and Transplant Registry: Experience and contributions to end-stage renal disease epidemiology. World J Nephrol. 2016;5(5):389-97.
50) Feehally J, Brusselmans A, Finkelstein FO, Harden P, Harris D, Manuzi G, et al. Improving global health: measuring the success of capacity building outreach programs: a view from the International Society of Nephrology. Kidney Int Suppl. 2016; 6(2): 42-51.
51) Harris DC, Dupuis S, Couser WG, Feehally J. Training nephrologists from developing countries: does it have a positive impact? Kidney Int Suppl. 2012;2(3):275-8.
52) Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Consensus Development Conference Panel. Ann Intern Med. 1994;121(1): 62-70.
53) García-García G, Martínez-Castellanos Y, Renoirte-Lopez K, Barajas-Murguia A, de la Torre-Campos L, Becerra-Muñóz LE, et al. Multidisciplinary care for poor patients with chronic kidney disease in Mexico. Kidney Int Suppl. 2013;3(2):178-83.
54) Stanifer JW, Von Isenburg M, Chertow GM, Anand S. Chronic kidney disease care models in low- and middle-income countries: a systematic review. BMJ Glob Health. 2018;3(2):e000728.
55) Narva AS, Norton JM, Boulware LE. Educating patients about CKD: the path to self-management and patient-centered care. Clin J Am Soc Nephrol. 2016;11(4):694-703.
56) Schatell D. Web-based kidney education: supporting patient self-management. Semin Dial. 2013;26(2):154-8.
Copyright (c) 2020 Revista de Nefrología, Diálisis y Trasplante
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.